Tissium Appoints Marc Quartulli as Vice President of Clinical Affairs
TISSIUM, a Medical Technology company, has appointed Marc Quartulli as its Vice President of Clinical Affairs to advance its clinical strategy and generate robust clinical evidence. Marc Quartulli brings extensive experience in clinical development and medical affairs across the medical device industry.
TISSIUM, a Medical Technology company pioneering biomorphic programmable polymers for tissue reconstruction, has appointed Marc Quartulli as its Vice President of Clinical Affairs. The company is based in Paris, France, and Cambridge, USA. Marc Quartulli has extensive experience in clinical development and medical affairs across the medical device industry, having served as Vice President, Clinical Affairs at AlvaMed, Inc. and held senior leadership roles at Conformis. TISSIUM's diversified pipeline includes one commercial product and six products in development across three core verticals: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. The company was founded in 2013 and is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer and Professor Jeffrey M. Karp.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.